| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Extension Agreement Follows Successful Two-Year Collaboration in Colon Cancer
PASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT) announced that it has signed an agreement to expand its collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute to study drug synergies of LIXTE's lead clinical compound, LB-100, with immunotherapy in various cancers. The new agreement also will seek to find synthetic lethal combinations in additional cancer types.
The two-year extension agreement follows successful collaboration during the past two years to identify the most promising drugs to be combined with LB-100 for treating colon cancer, as well as to identify the specific molecular mechanisms underlying the identified combinations in order to provide a rationale to test these combinations in clinical trials.
NKI, based in Amsterdam, Netherlands, is among the world's leading comprehensive cancer centers. Oncode Institute, headquartered in Utrecht, Netherlands, is a major independent cancer research center dedicated to translating research into practice and bringing discoveries into a clinic setting more quickly.
NKI's René Bernards, Ph.D., and his group – using genome-wide functional genetic techniques to identify effective drug combinations, new drug targets and mechanisms of resistance to cancer drugs – have identified a number of drug combinations that are now approved for patients or in advanced clinical development. Prof. Bernards is a professor of molecular carcinogenesis and has been a member of LIXTE's board of directors since June 2022.
"We are excited to continue and extend our work with LIXTE on additional types of cancer, as we look to identify the most powerful drug combinations of LB-100 for various cancer therapies," Prof. Bernards said. "In addition, we look forward to working with LIXTE to investigate the molecular mechanism of synergy of LB-100 with immune checkpoint therapy and testing of novel PP2A inhibitor molecules in cancer models."
Bas van der Baan, the recently appointed Chief Executive Officer and President of LIXTE, added, "The collaboration with Prof. Bernards and his team provides us with unique insights in our efforts to identify promising therapy combinations for LB-100 and a more targeted approach to cancer treatment."
Posted In: LIXT
